Han, Xuexiang http://orcid.org/0000-0003-0011-5222
Xu, Junchao http://orcid.org/0000-0003-0725-8111
Xu, Ying http://orcid.org/0000-0001-7341-8676
Alameh, Mohamad-Gabriel http://orcid.org/0000-0002-5672-6930
Xue, Lulu http://orcid.org/0000-0001-5719-1336
Gong, Ningqiang http://orcid.org/0000-0002-9444-8505
El-Mayta, Rakan http://orcid.org/0000-0002-5855-233X
Palanki, Rohan
Warzecha, Claude C. http://orcid.org/0000-0002-3659-2867
Zhao, Gan http://orcid.org/0000-0002-8043-6036
Vaughan, Andrew E. http://orcid.org/0000-0001-5740-643X
Wilson, James M. http://orcid.org/0000-0002-9630-3131
Weissman, Drew
Mitchell, Michael J. http://orcid.org/0000-0002-3628-2244
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 27 June 2023
Accepted: 26 January 2024
First Online: 26 February 2024
Competing interests
: X.H. and M.J.M. are inventors on a patent filed by the Trustees of the University of Pennsylvania (U.S. Provisional Patent Application No. 63/581,832, filed September 11, 2023) describing degradable branched lipid nanoparticle technology in this manuscript. JMW is a paid advisor to and holds equity in iECURE, Scout Bio, Passage Bio, and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies. He has sponsored research agreements with Amicus Therapeutics, CBM, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE, Passage Bio, and Scout Bio, which are licensees of Penn technology. J.M.W. is an inventor on patents that have been licensed to various biopharmaceutical companies and for which he may receive payments. All other authors declare no competing interests.